Back to top

Prelude Therapeutics Advances PRT3789 in Phase 1 Study for SMARCA4 Mutant Tumors

Prelude Therapeutics, Inc. (($PRLD)) announced an update on their ongoing clinical study. Prelude Therapeutics, Inc. is conducting a Phase 1 clinic...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Prelude Therapeutics Incorporated (PRLD)